Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging
© Müller et al. 2016
Received: 21 December 2015
Accepted: 13 April 2016
Published: 23 April 2016
Terbium has attracted the attention of researchers and physicians due to the existence of four medically interesting radionuclides, potentially useful for SPECT and PET imaging, as well as for α- and β−-radionuclide therapy. The aim of this study was to produce 152Tb (T 1/2 = 17.5 h, Eβ+av = 1140 keV) and evaluate it in a preclinical setting in order to demonstrate its potential for PET imaging. For this purpose, DOTANOC was used for targeting the somatostatin receptor in AR42J tumor-bearing mice.
152Tb was produced by proton-induced spallation of tantalum targets, followed by an online isotope separation process at ISOLDE/CERN. After separation of 152Tb using cation exchange chromatography, it was directly employed for radiolabeling of DOTANOC. PET/CT scans were performed with AR42J tumor-bearing mice at different time points after injection of 152Tb-DOTANOC which was applied at variable molar peptide amounts. 177Lu-DOTANOC was prepared and used in biodistribution and SPECT/CT imaging studies for comparison with the PET results.
After purification, 152Tb was obtained at activities up to ~600 MBq. Radiolabeling of DOTANOC was achieved at a specific activity of 10 MBq/nmol with a radiochemical purity >98 %. The PET/CT scans of mice allowed visualization of AR42J tumor xenografts and the kidneys, in which the radiopeptide was accumulated. After injection of large peptide amounts, the tumor uptake was reduced as compared to the result after injection of small peptide amounts. PET images of mice, which received 152Tb-DOTANOC at small peptide amounts, revealed the best tumor-to-kidney ratios. The data obtained with 177Lu-DOTANOC in biodistribution and SPECT/CT imaging studies confirmed the 152Tb-based PET results.
Production of 30-fold higher quantities of 152Tb as compared to the previously performed pilot study was feasible. This allowed, for the first time, labeling of a peptide at a reasonable specific activity and subsequent application for in vivo PET imaging. As a β+-particle-emitting radiolanthanide, 152Tb would be of distinct value for clinical application, as it may allow exact prediction of the tissue distribution of therapeutic radiolanthanides.
Terbium has attracted the attention of researchers in radiopharmaceutical sciences due to the existence of four medically interesting radionuclides for SPECT (155Tb) and PET (152Tb) imaging, as well as for α- (149Tb) and β−-radionuclide (161Tb) therapy. The first proof-of-concept study, using all four Tb radionuclides in combination with a folate-based tumor targeting agent, has been reported by Müller et al. . It was demonstrated that the production and preclinical application of these four Tb nuclides is feasible. Of the four Tb nuclides, 161Tb is the most advanced with regard to the production and separation methods, previously introduced by Zhernosekov et al.  and currently implemented at PSI . In vivo studies have been performed in order to assess the tissue distribution profile of 161Tb-labeled biomolecules and to investigate the therapeutic potential of 161Tb in comparison to the clinically- established 177Lu [3–5]. Based on the results of these studies, it is likely that the co-emitted Auger and conversion electrons of 161Tb contributed positively to the overall anti-tumor effects, while additional side effects to the kidneys were not observed . Another interesting Tb nuclide for therapeutic purposes is 149Tb, which decays with a half-life of 4 h and the emission of α-particles. Due to the currently limited availability of this radionuclide, extended in vitro and in vivo studies have not been performed yet. There is, however, a clear indication of its potential for α-radionuclide therapy, as demonstrated in preclinical proof-of-concept studies with 149Tb-labeled rituximab  as well as with a 149Tb-labeled DOTA-folate conjugate . Just recently, we demonstrated that 149Tb can also be used for PET imaging based on the emission of β+-particles .
Two other Tb nuclides, 155Tb and 152Tb, are suited for diagnostic applications. Recently, preclinical experiments were performed in order to investigate 155Tb in more detail with regard to its potential for SPECT imaging . For this purpose, several DOTA-functionalized tumor targeting agents, among those also peptides and an antibody, were employed for imaging of tumors in mice . The image quality of the 155Tb-based SPECT scans was convincing and allowed not only the visualization of subcutaneous tumor xenografts, but also smallest lesions in the abdominal tract of a mouse with intraperitoneal SKOV-3ip xenografts . 155Tb-based SPECT imaging was also investigated using a Derenzo phantom, which proved that the achievable image resolution was comparable to the resolution of 111In, a clinically well-established SPECT nuclide .
Decay properties of 152Tb based on NuDat 2.6 (www.nndc.bnl.gov/nudat2/)
Eβ+ average (I)
Significant γ-rays (I > 5 %); Eγ (I)
1140 (20.3 %)
271 (9.53 %); 344 (63.5 %); 586 (9.21 %); 779 (5.54 %)
Tumor-bearing mice were injected with the 152Tb-labeled peptide in order to assess the potential of 152Tb for PET imaging using a preclinical PET/CT scanner. The data obtained with 152Tb-DOTANOC were compared with the tissue distribution data and SPECT image obtained with the 177Lu-labeled counterpart in order to corroborate the hypothesis that 152Tb could serve as a surrogate for therapeutic radiolanthanides.
Production of 152Tb
152Tb was produced by 1.4 GeV proton-induced spallation in a tantalum foil target (55 g/cm2) at ISOLDE (CERN, Geneva, Switzerland). The spallation products were released online from the hot (~2000 °C) target and ionized in a hot (~2000 °C) tungsten ionizer. The cumulative 152Tb yields were significantly boosted by resonant laser ionization  of the radioactive precursor 152Dy. The ions were then accelerated to 30 keV and mass-separated, as previously reported [1, 15]. Mass 152 ions were implanted into zinc-coated gold foils.
Separation of 152Tb from target material and impurities
The zinc layer containing 152Tb, and other mass 152 impurities, was dissolved in 0.1 M HNO3/NH4NO3 at 80 °C. After addition of H2O, the solution was passed through a 50 mm × 5 mm column containing a macroporous strongly acidic cation exchange resin, as previously described . A concentration gradient of α-hydroxyisobutyric acid (α-HIBA; pH 4.7) ranging from 0.07, 0.09, 0.11 to 0.13 M was used for elution. The gradient pump was set to run at 0.33 mL/min, and ~1 mL fractions were collected in pre-washed Eppendorf tubes. Fractions containing the highest activity of 152Tb were used directly in the subsequent radiolabeling of DOTANOC.
Radiolabeling of DOTANOC
DOTANOC was obtained from ABX GmbH (DOTA-NOC acetate Cat-N° 9712). The peptide was dissolved in MilliQ water to obtain a stock solution of 1 mM. The radiolabeling with 152Tb was performed by direct addition of 12 μL DOTANOC stock solution to a 152Tb-α-HIBA solution (120 MBq in ~500 μL, pH 4.7). The reaction mixture was incubated at 95 °C for 15 min. Labeling of DOTANOC with n.c.a. 177Lu (Isotope Technologies Garching ITG GmbH, Germany) was performed under standard conditions in a mixture of HCl (0.05 M) and Na-acetate (0.5 M) at pH 4.5 and elevated temperature (15 min, 95 °C). High-performance liquid chromatography (HPLC) with a C-18 reversed-phase column (Xterra™ MS, C18, 5 μm, 150 × 4.6 mm; Waters) was used for quality control of the radiolabeled peptides. The mobile phase consisted of MilliQ water containing 0.1 % trifluoroacetic acid (A) and acetonitrile (B). A gradient from 95 % A and 5 % B to 20 % A and 80 % B over a period of 15 min was used with a flow rate of 1.0 mL/min. The product peak corresponding to 152Tb-DOTANOC and 177Lu-DOTANOC, respectively, appeared with a retention time (R t) of 11.1 min.
AR42J tumor cells, a rat exocrine pancreatic tumor cell line which is known to express the somatostatin receptor, were obtained from the European Collection of Cell Cultures (ECACC). The cells were cultured in RPMI 1640 medium, supplemented with 10 % fetal calf serum, l-glutamine, and antibiotics under standard conditions in a humidified atmosphere with 5 % CO2 at 37 °C. Routine culture was performed by trypsinization of the cells twice a week. To inoculate the animals, the cells were detached using trypsin, centrifuged, and resuspended in PBS at a concentration of 5 × 106 cells/100 μL.
Tumor mouse model
In vivo experiments were approved by the local veterinary department and conducted in accordance with the Swiss law of animal protection. Female nude mice (CD-1 Foxn-1/nu) were purchased from Charles River Laboratories (Sulzfeld, Germany). The animals were fed with a standard rodent chow ad libitum (Kliba Nafag, Kaiseraugst, Switzerland).
About 2 weeks prior to biodistribution and imaging studies, the mice were inoculated with AR42J tumor cells by subcutaneous injection of the cell suspension (5 × 106 cells/100 μL) on each shoulder.
Biodistribution study of 177Lu-DOTANOC in AR42J tumor-bearing mice
Biodistribution studies were performed in triplicate in AR42J tumor-bearing nude mice. 177Lu-DOTANOC (5 MBq, 2.5 nmol per mouse) was administered intravenously (i.v.) into a tail vein. Mice were euthanized at pre-determined time points between 30 min and 22 h after injection of the radioconjugate. Two additional groups of three mice each were injected with 5 MBq 177Lu-DOTANOC and a peptide amount of 0.5 and 5.0 nmol, respectively. Selected tissues and organs were collected, weighed, and counted for radioactivity using a γ-counter (Packard Canberra Cobra II, USA). The results were listed as a percentage of the injected activity per gram of tissue mass (% IA/g), using counts of a defined volume of the original injection solution measured at the same time.
SPECT/CT imaging studies
SPECT scans were performed after the injection of 177Lu-DOTANOC using a NanoSPECT/CT™ (Mediso Medical Imaging Systems, Budapest, Hungary) and Nucline Software (version 1.02, Bioscan Inc., Poway, USA). For this purpose, the energy peaks of 177Lu were set to 56.1 keV ± 10 %, 112.9 keV ± 10 %, and 208.4 keV ± 10 %. The acquired data were reconstructed using HiSPECT software (version 1.4.3049, Scivis GmbH, Göttingen, Germany). Images were prepared using the VivoQuant post-processing software (version 2.1, inviCRO Imaging Services and Software, Boston, USA). Accumulation of 177Lu-DOTANOC per volume of tumor and kidney tissue was determined using the “3D ROI” tool of the the VivoQuant post-processing software, allowing calculation of the tumor-to-kidney ratios. A Gauss post-reconstruction filter was applied for the presentation of the SPECT image, and the scale was adjusted to allow the best visualization of tumors and kidneys in which radioactivity accumulated.
PET/CT imaging studies
PET scans were performed with a bench-top preclinical PET/CT scanner (G8, Sofie Biosciences, California, USA and Perkin Elmer, Massachusetts, USA). The energy window ranged from 150 to 650 keV and the spatial resolution of reconstructed images was 1.4 mm full-width-at-half-maximum in the center of the field of view . The images were acquired as static whole-body scans using G8 acquisition software (version 18.104.22.168) and reconstructed with maximum-likelihood expectation maximization (MLEM). The data were corrected for random coincidences, decay and dead time. Images were prepared using the VivoQuant post-processing software (version 2.1, inviCRO Imaging Services and Software, Boston, USA). Accumulation of 152Tb-DOTANOC per volume of tumor and kidney tissue was determined using the “3D ROI” tool of the VivoQuant post-processing software, allowing calculation of the tumor-to-kidney ratios. A Gauss post-reconstruction filter was applied for the presentation of the PET, with the scale adjusted to allow the best visualization of tumors and kidneys in which radioactivity accumulated.
Production of 152Tb
Samples of ~1.3 GBq 152Tb were collected after online mass separation at the ISOLDE facility of CERN and implanted into Zn plated on gold foils. Collections were performed for 4-h periods utilizing a 2 μA, 1.4 GeV proton beam on the spallation target. After leaving the collected samples to stand, to allow the short-lived precursor, 152Dy, as well as 136Nd and 136Pr which are present as oxide sidebands to decay, the samples were transported to PSI. Radiochemical separation was performed 18 h after end of collection, when ~650 MBq 152Tb remained.
Separation of 152Tb
The radiochemical separation, based on cation exchange chromatography, saw the collection of 12 1-mL samples, yielding a total of ~600 MBq (>90 %) 152Tb in <2.5 mL 0.13 M α-HIBA. The gradient elution of the column at low pump speeds ensured the sole elution of 152Tb, leaving the remaining contaminants, predominantly Ce, to be eluted with more concentrated solutions. The 152Tb eluent was radiochemically pure and used directly for radiolabeling purposes.
Preparation of radiopeptides
The reaction mixture of 152Tb-DOTANOC and 177Lu-DOTANOC, respectively, was diluted with saline for in vivo application. Na-DTPA (5–10 μL, 5 mM, pH 5) was added for complexation of potential traces of unreacted 152Tb and 177Lu, respectively.
Biodistribution study of 177Lu-DOTANOC in AR42J tumor-bearing mice
Biodistribution studies were performed in AR42J tumor-bearing nude mice at 30 min, 2 h, 5 h, 16 h, and 22 h after injection of 177Lu-DOTANOC (5 MBq/2.5 nmol) in order to quantify the tissue distribution of radioactivity (Table 3). Based on the data obtained in these experiments, the radioconjugate was quickly cleared from the blood and accumulated in the tumor tissue, where it reached a maximum uptake of 9.02 ± 0.33 % IA/g already 30 min after injection. Over the first 5 h, the uptake in the tumor remained almost constant, but it decreased later to 5.48 ± 0.98 % IA/g at 16 h and 4.51 ± 0.37 % IA/g at 22 h after injection. In the kidneys, the highest value of accumulated radioactivity (13.0 ± 1.85 % IA/g) was determined 30 min after injection of 177Lu-DOTANOC. The radioactivity was cleared from the kidneys over time, resulting in 4.80 ± 0.19 % IA/g at 22 h after injection. As a consequence, the tumor-to-kidney ratios were ~1 within the time window of 2 to 22 h after injection of 177Lu-DOTANOC applied at the mentioned molar peptide amount.
PET/CT and SPECT/CT imaging studies
Experimental design of the PET/CT and SPECT/CT imaging studies
Injected activity (IA)
Scan start (scan duration)
Radioactivity at scan start
2 h p.i. (20 min)
5 h p.i. (20 min)
8 h p.i. (20 min)
22 h p.i. (20 min)
22 h p.i. (30 min)
32 h p.i. (30 min)
Additional file 1: Fig. S1a
22 h p.i. (4 h)b
Biodistribution of 177Lu-DOTANOC (5 MBq/2.5 nmol) in AR42J tumor-bearing female nude mice, expressed in percentage of total injected activity per gram tissue (% IA/g)
30 min p.i.
2 h p.i.
5 h p.i.
16 h p.i.
22 h p.i.
2.52 ± 0.65
0.09 ± 0.01
0.06 ± 0.01
0.07 ± 0.01
0.03 ± 0.00
1.34 ± 0.35
0.08 ± 0.01
0.07 ± 0.01
0.07 ± 0.01
0.03 ± 0.00
3.04 ± 0.47
0.45 ± 0.03
0.41 ± 0.04
0.27 ± 0.05
0.21 ± 0.03
0.77 ± 0.03
0.15 ± 0.01
0.18 ± 0.02
0.13 ± 0.04
0.09 ± 0.01
13.0 ± 1.85
7.67 ± 0.51
9.10 ± 1.66
6.13 ± 1.63
4.80 ± 0.19
1.38 ± 0.32
0.28 ± 0.14
0.37 ± 0.05
0.51 ± 0.40
0.42 ± 0.18
1.95 ± 0.23
1.14 ± 0.04
1.21 ± 0.55
0.68 ± 0.09
0.60 ± 0.22
1.99 ± 0.07
1.09 ± 0.17
0.88 ± 0.11
0.34 ± 0.05
0.25 ± 0.03
0.94 ± 0.12
0.25 ± 0.04
0.25 ± 0.03
0.16 ± 0.01
0.13 ± 0.03
1.43 ± 0.17
0.52 ± 0.04
0.53 ± 0.10
0.27 ± 0.05
0.20 ± 0.02
0.48 ± 0.16
0.02 ± 0.00
0.02 ± 0.01
0.03 ± 0.00
0.01 ± 0.00
1.13 ± 0.26
0.17 ± 0.01
0.12 ± 0.02
0.12 ± 0.05
0.08 ± 0.01
0.06 ± 0.01
0.01 ± 0.00
0.02 ± 0.00
0.02 ± 0.01
0.01 ± 0.00
9.02 ± 0.33
8.32 ± 0.47
8.45 ± 1.04
5.48 ± 0.98
4.51 ± 0.37
3.76 ± 1.05
96.6 ± 8.79
137 ± 15.3
80.0 ± 8.30
180 ± 17.5
6.39 ± 0.89
16.1 ± 1.34
16.2 ± 2.10
21.0 ± 2.68
23.0 ± 2.96
0.71 ± 0.11
1.09 ± 0.06
0.94 ± 0.16
0.93 ± 0.19
0.94 ± 0.02
There are only few instances in preclinical studies where 152Tb has been used [1, 17]. The present study is the first in which 152Tb (available at ~30-fold higher quantities) could be employed for detailed in vivo PET imaging using tumor-bearing mice and a well-established somatostatin receptor targeting peptide. A unique and indisputable advantage of 152Tb, as compared to currently used 68Ga, is the possibility to use it for imaging purposes over a longer period. It may find application as a diagnostic and dosimetry match for clinically-used therapeutic radionuclides, such as 177Lu and 166Ho, or for the exact therapeutic matches 161Tb and 149Tb. In this regard, it may be of particular value in combination with targeting agents of a longer biological half-life such as albumin-binding small molecules or antibodies. Although other longer-lived PET nuclides such as 89Zr (T 1/2 = 3.26 days) and 64Cu (T 1/2 = 12.7 h) exist, these nuclides have different chemical properties and, hence, different chelators are necessary for stable coordination [18–20]. 68Ga is currently successfully used for PET imaging prior to 177Lu-based radionuclide therapy [11, 21], however, its short half-life and different coordination chemistry, which may result in different pharmacokinetics , would clearly speak in the favor of using a matched radiolanthanide for PET and, thus, justify the development and investigation of 152Tb.
In the proof-of-concept study in which 152Tb was used for the first time in vivo, only 20 MBq of 152Tb were available after separation, allowing labeling of a DOTA-folate conjugate at a low specific activity of 1.3 MBq/nmol . As a consequence, relatively high molar amounts of the folate conjugate (~7 nmol) had to be injected in order to only obtain PET images at short time points (1.5 and 3 h) after injection, while imaging the following day was only possible post-mortem due to the long acquisition time which was required . In the present study, a ~30-fold increased activity was obtained allowing radiolabeling at a markedly higher specific activity of 10 MBq/nmol. Such improvement was feasible due to significantly higher activities which were produced, allowing the performance of the radiolabeling with higher activity concentrations.
Partial degradation of the peptide, as a consequence of radiolysis, was observed as a shoulder of the product peak—a phenomenon which is more pronounced with increasing radioactivity concentrations. The addition of ascorbic acid or gentisic acid to the labeling solution would, most likely, prevent this process completely, as previously demonstrated by our group when using 44Sc (Eβ+av = 632 keV, Iβ+ = 94 %, Eγ = 1157 keV, Iγ = 99.9 %; T 1/2 = 3.97 h) for labeling of the same peptide . It will be of interest to investigate the extent of radiolysis with 152Tb-labeled peptides in more detail in future experiments. In addition, comparison with peptides, labeled with conventional PET nuclides like 68Ga, would be interesting and allow the development of suitable labeling and storage conditions under the application of commonly used scavengers.
The high sensitivity G8 PET/CT scanner allowed the performance of PET scans with low activities within a short acquisition time. It was, therefore, possible for the first time to perform in vivo PET/CT scans up to 22 h after administration of the 152Tb-labeled compound.
The mouse which received 47 MBq 152Tb-DOTANOC was also successfully scanned at 32 h after injection as the longest time point of investigation (Additional file 1: Fig. S1).
The PET/CT experiments performed in this study corroborated the hypothesis that 152Tb can be used as a diagnostic match to 177Lu, as the images reflected what was expected based on biodistribution experiments using 177Lu-DOTANOC. It was also demonstrated that the molar amount of injected peptide was crucial with regard to the tumor uptake of radioactivity and, as a result, the tumor-to-kidney ratios. These findings are in agreement with previous findings reported in the literature, which showed that therapeutic quantities of injected peptide may saturate the receptors in somatostatin receptor-positive tissue . In the present study, low peptide amounts (0.5 nmol) showed a clearly higher tumor uptake (~25 % IA/g, 5 h p.i.) as compared to 10-fold higher peptide amounts which resulted in a markedly reduced accumulation in the tumor (~4 % IA/g, 5 h p.i.). These findings were also reflected by the fact that excretion of radioactivity injected into mice was slower if small amounts of peptide were used because, in this case, a larger fraction was accumulated and retained in the tumor tissue (Additional file 1: Fig. S2). Such results are, however, dependent on the tumor type, the tumor size, and its receptor expression level. It may be different for other targeting agents and, hence, such effects have to be carefully evaluated for each single targeting concept and tumor mouse model. In the case of using DOTANOC in AR42J tumor-bearing mice, our results clearly demonstrated how crucial it would be to inject the same peptide amount for diagnosis and therapy in order to allow visualization of the effective tissue distribution expected for the therapeutic match.
While the limited availability of 152Tb was considered as a hindrance for further investigations to date, new endeavors are focused on overcoming this obstacle. The present study demonstrated an increase in obtained radioactivity by a factor 30 with respect to our previously published pilot study . In the near future, it is foreseen to increase the 152Tb activities further by using thicker tantalum targets that may result in a gain of a factor 2-4, as well as longer collection times resulting in an additional gain of activity of up to a factor 6.
MEDICIS, a new radionuclide production center dedicated to medical applications, is being built at CERN (Geneva, Switzerland). Other facilities exploiting spallation production combined with isotope separation online are under operation at ISAC, TRIUMF (Vancouver, Canada) and IRIS, PNPI (Gatchina, Russia). New facilities are planned or under construction at RIBF (East Lansing, USA), ISOL@MYRRHA (Mol, Belgium), and J-PARC ISOL (Tokai, Japan). Such facilities will provide about two orders of magnitude higher proton current on target compared to the proton current used for the present study, thus, the production of 152Tb by spallation and coupled to mass separation has the potential to produce in the range of TBq per day. Such activity would correspond to several hundreds of patient doses. Alternative production at compact cyclotrons via the 152Gd (p,n)152Tb reaction with 12 MeV protons, followed by radiochemical Gd/Tb separation  is feasible once highly enriched 152Gd becomes commercially available. One can assume that the more regular production of 152Tb will be possible in the near future and provide quantities sufficient for pilot investigations in patients.
In this study, 152Tb was produced at significantly higher quantities (30 times more) than previously achieved. These circumstances allowed the performance of more detailed imaging studies with tumor-bearing mice using in vivo PET/CT. Based on the resulting data, 152Tb is a promising candidate to be used as diagnostic match to therapeutic radiolanthanides, potentially allowing exact pre-therapeutic imaging and dosimetry calculations. More regular production of 152Tb at high quantities will be crucial to allow further preclinical investigations, as well as pilot studies in the clinics.
Compliance with ethical standards
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
This article does not contain any studies with human participants performed by any of the authors.
The authors thank Susan Cohrs for technical assistance at PSI, the ISOLDE RILIS team for efficient laser ionization, and the ISOLTRAP collaboration, especially Dr. Vladimir Manea and Frank Wienholtz, for the characterization of the ISOLDE beam using the MR-TOF spectrometer (ISOLDE/CERN).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β--radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. 2012;53:1951–9. doi:10.2967/jnumed.112.107540.View ArticlePubMedGoogle Scholar
- Lehenberger S, Barkhausen C, Cohrs S, Fischer E, Grunberg J, Hohn A, et al. The low-energy beta- and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nucl Med Biol. 2011;38:917–24. doi:10.1016/j.nucmedbio.2011.02.007.View ArticlePubMedGoogle Scholar
- de Jong M, Breeman WA, Bernard BF, Rolleman EJ, Hofland LJ, Visser TJ, et al. Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med. 1995;22:608–16.View ArticlePubMedGoogle Scholar
- Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014;41:476–85. doi:10.1007/s00259-013-2563-z.View ArticlePubMedGoogle Scholar
- Grünberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhernosekov K, Köster U, et al. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. Eur J Nucl Med Mol Imaging. 2014;41:1907–15. doi:10.1007/s00259-014-2798-3.View ArticlePubMedGoogle Scholar
- Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, Köster U, Bernhardt P, et al. Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Res. 2016;6:13. doi:10.1186/s13550-016-0171-1.View ArticlePubMedPubMed CentralGoogle Scholar
- Beyer GJ, Comor JJ, Dakovic M, Soloviev D, Tamburella C, Hagebo E, et al. Production routes of the alpha emitting 149Tb for medical application. Radiochim Acta. 2002;90:247–52. doi:10.1524/ract.2002.90.5_2002.247.View ArticleGoogle Scholar
- Müller C, Reber J, Haller S, Dorrer H, Köster U, Johnston K, et al. Folate receptor targeted alpha-therapy using terbium-149. Pharmaceuticals (Basel). 2014;7:353–65. doi:10.3390/ph7030353.View ArticleGoogle Scholar
- Müller C, Vermeulen C, Köster U, Johnston K, Türler A, Schibli R, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. Eur J Nucl Med Mol Imaging Radiopharm Chem. 2016;in press.Google Scholar
- Müller C, Fischer E, Behe M, Köster U, Dorrer H, Reber J, et al. Future prospects for SPECT imaging using the radiolanthanide terbium-155—production and preclinical evaluation in tumor-bearing mice. Nucl Med Biol. 2014;41(Suppl):e58–65. doi:10.1016/j.nucmedbio.2013.11.002.View ArticlePubMedGoogle Scholar
- Ambrosini V, Campana D, Polverari G, Peterle C, Diodato S, Ricci C, et al. Prognostic value of 68Ga-DOTA-NOC PET/CT SUVmax in patients with neuroendocrine tumours of the pancreas. J Nucl Med. 2015. doi:10.2967/jnumed.115.162719.PubMedGoogle Scholar
- Sharma P, Arora S, Mukherjee A, Pal S, Sahni P, Garg P, et al. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified? Clin Nucl Med. 2014;39:37–43. doi:10.1097/RLU.0000000000000257.View ArticlePubMedGoogle Scholar
- Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC. Recent Results Cancer Res. 2013;194:519–36. doi:10.1007/978-3-642-27994-2_30.View ArticlePubMedGoogle Scholar
- Köster U. Resonance ionization laser ion sources. Nucl Phys A. 2002;701:441c–51c.View ArticleGoogle Scholar
- Allen BJ, Goozee G, Sarkar S, Beyer G, Morel C, Byrne AP. Production of terbium-152 by heavy ion reactions and proton induced spallation. Appl Radiat Isot. 2001;54:53–8.View ArticlePubMedGoogle Scholar
- Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, et al. Evaluation of the Genisys4, a bench-top preclinical PET scanner. J Nucl Med. 2013;54:1162–7. doi:10.2967/jnumed.112.114926.View ArticlePubMedPubMed CentralGoogle Scholar
- Rizvi SMA, Henniker AJ, Goozee G, Allen BJ. In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. Leukemia Res. 2002;26:37–43.View ArticleGoogle Scholar
- Fischer G, Seibold U, Schirrmacher R, Wängler B, Wängler C. 89Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules. 2013;18:6469–90. doi:10.3390/molecules18066469.View ArticlePubMedGoogle Scholar
- Severin GW, Engle JW, Barnhart TE, Nickles RJ. 89Zr radiochemistry for positron emission tomography. Med Chem. 2011;7:389–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24:379–93. doi:10.1089/cbr.2009.0674.View ArticlePubMedPubMed CentralGoogle Scholar
- Sharma P, Dhull VS, Arora S, Gupta P, Kumar R, Durgapal P, et al. Diagnostic accuracy of 68Ga-DOTANOC PET/CT imaging in pheochromocytoma. Eur J Nucl Med Mol Imaging. 2014;41:494–504. doi:10.1007/s00259-013-2598-1.View ArticlePubMedGoogle Scholar
- Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:501–11. doi:10.1007/s00259-011-2003-x.View ArticlePubMedGoogle Scholar
- van der Meulen NP, Bunka M, Domnanich KA, Müller C, Haller S, Vermeulen C, et al. Cyclotron production of 44Sc: from bench to bedside. Nucl Med Biol. 2015;42:745–51. doi:10.1016/j.nucmedbio.2015.05.005.View ArticlePubMedGoogle Scholar
- Müller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP, et al. Diagnostic versus therapeutic doses of [177Lu-DOTA-Tyr3]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. Cancer Biother Radiopharm. 2007;22:151–9. doi:10.1089/cbr.2007.309.View ArticlePubMedGoogle Scholar
- Vermeulen C, Steyn GF, Szelecsenyi F, Kovacs Z, Suzuki K, Nagatsu K, et al. Cross sections of proton-induced reactions on natGd with special emphasis on the production possibilities of 152Tb and 155Tb. Nucl Instrum Methods Phys Res Sect B-Beam Interact Mater Atoms. 2012;275:24–32.View ArticleGoogle Scholar